Literature DB >> 22331060

Pediatric rheumatic disease: Vaccination in pediatric rheumatic disease--risks and benefits.

Ginger Janow, Norman T Ilowite.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22331060     DOI： 10.1038/nrrheum.2012.13

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego.

Authors:  Carlo Perricone; Nancy Agmon-Levin; Guido Valesini; Yehuda Shoenfeld
Journal:  Joint Bone Spine       Date:  2011-11-26       Impact factor: 4.929

2.  Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.

Authors:  Nadia E Aikawa; Lucia M A Campos; Clovis A Silva; Jozelio F Carvalho; Carla G S Saad; Guilherme Trudes; Alberto Duarte; Joao L Miraglia; Maria do Carmo S Timenetsky; Vilma S T Viana; Ivan L A França; Eloisa Bonfa; Rosa M R Pereira
Journal:  J Rheumatol       Date:  2011-11-15       Impact factor: 4.666

Review 3.  'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants.

Authors:  Yehuda Shoenfeld; Nancy Agmon-Levin
Journal:  J Autoimmun       Date:  2010-08-13       Impact factor: 7.094

Review 4.  The new H1N1 and HPV vaccines and old fears.

Authors:  Ari Balofsky; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Curr Opin Rheumatol       Date:  2010-07       Impact factor: 5.006

5.  EULAR recommendations for vaccination in paediatric patients with rheumatic diseases.

Authors:  M W Heijstek; L M Ott de Bruin; M Bijl; R Borrow; F van der Klis; I Koné-Paut; A Fasth; K Minden; A Ravelli; M Abinun; G S Pileggi; M Borte; N M Wulffraat
Journal:  Ann Rheum Dis       Date:  2011-08-03       Impact factor: 19.103

6.  Impaired in vivo and in vitro antibody responses to bacteriophage phi X 174 in juvenile rheumatoid arthritis.

Authors:  N T Ilowite; R J Wedgwood; L M Rose; E A Clark; C G Lindgren; H D Ochs
Journal:  J Rheumatol       Date:  1987-10       Impact factor: 4.666

7.  Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.

Authors:  Laura Dell'Era; Fabrizia Corona; Cristina Daleno; Alessia Scala; Nicola Principi; Susanna Esposito
Journal:  Vaccine       Date:  2011-12-03       Impact factor: 3.641

8.  Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.

Authors:  Pirjo Tynjälä; Paula Vähäsalo; Maarit Tarkiainen; Liisa Kröger; Kristiina Aalto; Merja Malin; Anne Putto-Laurila; Visa Honkanen; Pekka Lahdenne
Journal:  Ann Rheum Dis       Date:  2011-05-28       Impact factor: 19.103

9.  Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children.

Authors:  Caroline B Long; Irene Ramos; Deepa Rastogi; Deepa Manwani; Ginger Janow; Marcela Del Rio; Marguerite Mayers; Betsy C Herold; Ana Fernandez-Sesma; Rebecca Pellett Madan
Journal:  J Pediatr       Date:  2011-08-15       Impact factor: 4.406

10.  Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.

Authors:  Maria Rehnberg; Mikael Brisslert; Sylvie Amu; Kiandoht Zendjanchi; Gunilla Håwi; Maria I Bokarewa
Journal:  Arthritis Res Ther       Date:  2010-06-08       Impact factor: 5.156
  10 in total
  1 in total

Review 1.  Vaccinations in juvenile chronic inflammatory diseases: an update.

Authors:  Clovis A Silva; Nadia E Aikawa; Eloisa Bonfa
Journal:  Nat Rev Rheumatol       Date:  2013-07-02       Impact factor: 20.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.